There is a specific type of scientific scrutiny that companies rarely invite and almost never publicize: the independent assessment conducted not for marketing purposes but for investor and regulatory due diligence. This is a review where the reviewer has no relationship with the company, no interest in a favorable outcome, and every reason to be skeptical — because the people reading the report are making financial and regulatory decisions.
In September 2019, as part of the due diligence process preceding Aires’ public market listing on the Canadian Securities Exchange, the lead underwriting institution commissioned exactly this type of review. A credentialed biophysicist with expertise in bioelectromagnetics and heart rate variability research — someone who had published their own peer-reviewed work using the same measurement methods used in several Aires studies — was asked to evaluate the Aires technology and the complete body of research supporting it, and to give banks and regulatory bodies in the US, Canada, and the EU an honest scientific opinion about whether the company represented an investable or inadvisable risk.
What the reviewer found — and what the research program built in the years that followed — is one of the clearest illustrations available of how the science behind Lifetune has developed.
What the 2019 Review Found
The reviewer assessed the research corpus as it stood in mid-2019: approximately two dozen study reports covering physics, biology, water biophysics, and early human measurements, plus the patent portfolio. The assessment was candid. Some early studies had methodological limitations. Several were preliminary. The theoretical explanation of the mechanism needed more rigorous development.
But the overall conclusion, stated directly in the final report, was this:
“The scientific evidence collectively points to the conclusion that the Aires technology: (1) produces measurable changes in applied electromagnetic radiation associated with wireless communication devices; (2) affects certain physical parameters of water, the matrix of life; (3) shows a protective effect on rat cells taken from rats exposed to electromagnetic radiation in laboratory experiments; and (4) shows very limited evidence of protective effects on humans. Based on this range of evidence, the technology appears to be a promising new protective modality... it would be worth investing in the company at this time.”
The reviewer specifically highlighted two studies as standing out for their quality. The Havas cardiovascular case study (Trent University, Canada, 2015) was described as “an excellent study in terms of research design and reporting” — a double-blind protocol using FDA Class II measurement equipment on a subject with electromagnetic hypersensitivity. The Dyuzhikova chromosome aberration study (published in a peer-reviewed journal, 2018) was described as “well-designed, well-reported.”
The VGTU engineering testing program (Vilnius Gediminas Technical University, Lithuania) was noted as important because it demonstrated measurable effects of the Aires technology on electromagnetic fields and established operating parameters.
What the Review Recommended
The reviewer was direct about what the research program needed to do next. Several specific recommendations were made:
Controlled human clinical trials. “Clinical trials are most critical to perform. Randomized, sham-controlled, double-blinded clinical studies on human subjects exposed under controlled laboratory conditions to the radiation emanating from typical wireless communication devices... are needed to empirically validate purported protective effects on humans.”
Larger scale studies with statistical analysis. The Havas protocol, the reviewer said, “would be worth repeating with a larger group of subjects such that statistical analysis could be done, and then it could be published in a peer-reviewed health journal.”
Physical characterization of the field changes. A complete waveform analysis of how the Aires resonator changes an applied electromagnetic field was recommended, including oscillogram documentation at WiFi and 5G frequencies.
International patent protection. The reviewer noted that intellectual property protection should be extended internationally through PCT filings.
“With a strong and dedicated research program,” the report concluded, “this company has the potential to become a leader in applications to protect humanity from the ravages of wireless communication radiation.”
What the Research Program Built in Response
The 2019 review read the state of the evidence accurately for its time. And since 2019, the research program has responded to almost every gap it identified.
On controlled human studies: The Military Medical Academy (VMA) 2024 study enrolled 24 human subjects in a quantitative EEG protocol with five distinct measurement stages — testing Lifetune ONE under mobile phone EMF exposure. This is precisely the controlled human study the reviewer called for. The Sysoev-Rybina 2025 study ran a 5-stage EEG protocol using Lifetune ONE, the most elaborate human EEG protocol in the research history. Both found EEG normalization consistent with studies going back to 2003.
On larger replications: The IFRAN Pavlov Institute animal study program continued through 2025, extending findings across five biological endpoints, two rat genotypes, and — in the most recent study — to WiFi6 using the current Lifetune Zone Max. The Dyuzhikova study that the reviewer called “well-designed” was confirmed and extended by subsequent research at the same institute.
On physical characterization: Prof. Gennadi Lukyanov at ITMO University published a Springer conference paper in 2022 presenting a full computer simulation of the Lifetune resonator’s electromagnetic response. His Stage 2 ITMO report (2025) extended this to multi-resonator arrays and confirmed the model using thermal imaging with a calibrated Testo 890 thermal camera — exactly the physical documentation the reviewer described as essential. These findings were presented internationally at ICICT 2026.
On international patent protection: PCT filing WO 2021/064446 was filed in October 2019 (the same month the due diligence review was completed) and designated in major markets. US Patent US12239835B2 was granted on March 4, 2025, assigned to American Aires Inc. in June 2026 — covering the core technology from 2.4 GHz to 28 GHz across all current wireless frequencies.
Why This Matters
The 2019 due diligence review is significant for several reasons beyond its conclusions.
First, it establishes what an independent expert — someone with no financial stake in the outcome and every professional reason to be rigorous — found when she reviewed the research and technology in their early state. She found enough to recommend investment and to call the technology “promising.”
Second, it establishes a clear baseline. The review described what was missing in 2019. The research program built exactly what was described as missing. That sequence — gaps identified by an independent expert, then filled by the subsequent research program — is evidence of something more than promotional science.
Third, it demonstrates that the research program has not operated in isolation. External scientists with no obligation to be favorable have consistently evaluated this research. The PACE independent peer reviews (seven in total, from a UN ECOSOC-affiliated Canadian organization), the Havas studies from Trent University, the Dyuzhikova peer-reviewed publication in Ecological Genetics, and the Springer publication of the Lukyanov modeling paper — all of these represent external eyes on the science, reaching positive conclusions.
The picture that emerges is not of a company producing its own validating research. It is a company that invited external scrutiny at a critical moment, received an honest assessment of what was strong and what was lacking, and spent the subsequent years building exactly what the assessment said was needed.
The Research Today
In 2019, the independent reviewer concluded the technology was “promising” based on early-stage research. The research program has since added:
- Two controlled human EEG studies using current Lifetune ONE (VMA 2024, Sysoev-Rybina 2025)
- A Springer-published computer simulation of the resonator mechanism (Lukyanov 2022)
- Thermal imaging physical validation of the mathematical model (ITMO 2025, ICICT 2026)
- Extension of the WiFi biological findings to WiFi6 (SFERA/Pavlov Institute 2025)
- A granted US patent protecting the technology in the world’s largest consumer market
- Adoption by the UFC Performance Institute for use with elite professional athletes
The science was promising in 2019. It is substantially more than promising now.